Red List

INBXInhibrx Biosciences, Inc.

Healthcare · Biotechnology · small-cap ($1.2B)
-36.1%
from rolling 252-day high of $155.29 set 2026-04-22 · 120d ago
Current
$99.15
Decline depth
-36.1%
Decline σ
1.4σ
TFC
3/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Since tracking began

$INBX has been tracked since 2026-03-01. It was down 18.1% from its 52-week high then — now down -36.1%.

It has clawed back 27.7 percentage points off that level. It bottomed 38.3% below that high along the way.

Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.

Structural break signals

INBX qualifies for the Red List on decline depth.

Decline depth
-36.1%
From rolling 252-day high of $155.29, 120d ago. Past the 30% Amber threshold.
Time-frame continuity
3/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3. Past the 3/5 Watch threshold.
Decline sigma
1.4σ
Drop from local high over the last 5 bars, expressed in units of the stock's typical daily volatility (4.12% per day).

The structural read

What price action says about INBX.

INBX qualifies for the Red List on decline depth — down -36.1% from its rolling 252-day high. Past 30% with the high set inside the last four months — the recency clause that often precedes further breakdown. Depth plus recency: this is the pattern many investors call a falling knife.

Cross-confirmation: also showing 3/5 bearish time frames.

Earnings on file: 2026-05-14. Tiering is unaffected by earnings dates — listings reflect price structure only.

Questions about INBX

What people ask.

Why is INBX on Broken Stocks?

INBX qualifies for the Red List on decline depth. It is down -36.1% from its rolling 252-day high of $155.29, set on 2026-04-22 — 120d ago.

Is INBX a falling knife?

By the most common technical definition — a steep, recent breakdown from a fresh high — yes. INBX is down -36.1% from its 52-week high of $155.29, set 120d ago. That combination of depth (past the 30% Amber threshold) and recency (high set inside the last 120 days) is the textbook falling-knife pattern. Whether to try to catch it is a separate question — historically most attempts to bottom-pick continue lower before reversing. Broken Stocks flags the pattern; it does not recommend buying or selling.

Is INBX a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is INBX trading inside its 52-week range?

At $99.15, INBX sits 58.3% of the way from its 52-week low ($20.55) to its 52-week high ($155.29). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has INBX been declining?

The current 36.1% decline accrued over 120d, which annualizes to roughly -109.8% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does INBX compare to its sector?

There are 143 other Healthcare tickers on Broken Stocks: 69 Red, 35 Amber, 39 Watch, with 50 showing recovering structural signals. Median sector decline is -36.1% — INBX's decline is shallower than the sector median.

Does INBX's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-05-14) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.